ReviewCurrent atherosclerosis reports2026
Triglyceride-Rich Lipoproteins and Inflammation: Independent and Synergistic Roles in Cardiovascular Disease.
Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
purpose of reviewTo summarize novel insights regarding the independent and combined roles of triglyceride-rich lipoprotein elevations and low-grade inflammation in cardiovascular disease. RECENT
findingsEmerging evidence suggest that triglyceride-rich lipoproteins are more atherogenic than LDL particles, and that remnant cholesterol drives the association with cardiovascular risk. In contemporary secondary prevention, elevated hsCRP is a stronger predicter of cardiovascular events than LDL cholesterol, while in primary prevention, hsCRP and LDL cholesterol equally predict risk of future cardiovascular disease. Some anti-inflammatory trials do not support the use of colchicine in acute coronary syndrome; however, results from recent meta-analyses strongly support colchicine therapy for secondary cardiovascular prevention. Finally, epidemiological and genetic studies indicate that triglyceride-rich lipoproteins cause vascular inflammation, although both risk factors appear to contribute synergistically to cardiovascular risk. Triglyceride-rich lipoprotein elevations and low-grade inflammation are important, independent cardiovascular risk factors. More research is needed to further characterize their potential interplay in cardiovascular disease and validate never therapies.
Indexed as
Identifiers
41770241What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.